MCID: ACT008
MIFTS: 56

Actinic Keratosis

Categories: Skin diseases, Genetic diseases, Cancer diseases

Aliases & Classifications for Actinic Keratosis

MalaCards integrated aliases for Actinic Keratosis:

Name: Actinic Keratosis 12 72 51 14 69
Senile Hyperkeratosis 12
Seborrheic Keratosis 69
Sk - Solar Keratosis 12
Actinic Keratosis 12
Keratosis, Actinic 41
Solar Keratosis 12

Classifications:



Summaries for Actinic Keratosis

MalaCards based summary : Actinic Keratosis, also known as senile hyperkeratosis, is related to keratosis and bowen's disease. An important gene associated with Actinic Keratosis is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Mitotic G1-G1/S phases and MicroRNAs in cancer. The drugs Picato gel and Aminolevulinic acid have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and kidney, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 72 Actinic keratosis (AK) is a pre-cancerous patch of thick, scaly, or crusty skin. These growths are more... more...

Related Diseases for Actinic Keratosis

Diseases in the Actinic Keratosis family:

Keratosis, Familial Actinic

Diseases related to Actinic Keratosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 148)
# Related Disease Score Top Affiliating Genes
1 keratosis 33.0 CDKN2A KRT17 TP53
2 bowen's disease 31.1 KRT17 PCNA
3 squamous cell carcinoma 31.0 CDKN2A MMP2 PTGS2 TP53 TP63
4 basal cell carcinoma 30.0 CDKN2A KRT17 KRT20 MC1R TP53 TP63
5 papilloma 29.4 CDKN2A KRT20 PCNA TP53 TP63
6 actinic cheilitis 11.2
7 brain stem astrocytic neoplasm 10.6 CDKN2A TP53
8 squamous cell carcinoma of the oropharynx 10.6 CDKN2A TP53
9 spitz nevus 10.5 CDKN2A TP53
10 basal cell carcinoma 1 10.5
11 protoplasmic astrocytoma 10.5 PTGS2 TP53
12 vulvar intraepithelial neoplasia 10.5 MMP2 TP53
13 keratinizing squamous cell carcinoma 10.5 CDKN2A TP53
14 bartholin's gland benign neoplasm 10.5 CDKN2A TP53
15 bowenoid papulosis 10.5 CDKN2A PTGS2
16 multicentric osteolysis, nodulosis, and arthropathy 10.5 MMP14 MMP2
17 winchester syndrome 10.5 MMP14 MMP2
18 bladder carcinoma in situ 10.5 CDKN2A TP53
19 anal squamous cell carcinoma 10.5 CDKN2A TP53
20 bizarre leiomyoma 10.5 CDKN2A PCNA
21 bladder papillary transitional cell neoplasm 10.5 KRT20 TP53
22 urinary tract papillary transitional cell benign neoplasm 10.5 KRT20 TP53
23 thyroid lymphoma 10.4 CDKN2A TP53
24 mucinous bronchioloalveolar adenocarcinoma 10.4 CDKN2A KRT20
25 vulva squamous cell carcinoma 10.4 CDKN2A TP53
26 vulval paget's disease 10.4 CDKN2A KRT20
27 balanitis xerotica obliterans 10.4 CDKN2A PTGS2 TP53
28 bladder squamous cell carcinoma 10.4 CDKN2A PTGS2 TP53
29 esophagus adenocarcinoma 10.4 CDKN2A PTGS2 TP53
30 tongue squamous cell carcinoma 10.4 CDKN2A MMP2 TP53
31 nasal cavity adenocarcinoma 10.4 CDKN2A TP53
32 tongue cancer 10.4 CDKN2A MMP2 TP53
33 barrett's adenocarcinoma 10.4 CDKN2A PTGS2 TP53
34 gastrointestinal system benign neoplasm 10.4 CDKN2A PTGS2 TP53
35 female reproductive organ cancer 10.4 CDKN2A MMP2 TP53
36 juvenile pilocytic astrocytoma 10.4 CDKN2A TNC TP53
37 bone squamous cell carcinoma 10.4 CDKN2A TP53
38 lentigo maligna melanoma 10.4 MC1R MMP2
39 reproductive organ cancer 10.4 CDKN2A MMP2 TP53
40 squamous cell carcinoma of the larynx 10.4 CDKN2A PCNA TP53
41 cystic basal cell carcinoma 10.4 KRT20 TP63
42 proliferative verrucous leukoplakia 10.4 CDKN2A MCM2
43 oral leukoplakia 10.4 CDKN2A PCNA TP53
44 suppressor of tumorigenicity 3 10.4 CDKN2A PCNA TP53
45 megaesophagus 10.4 CDKN2A TP53
46 malignant syringoma 10.4 KRT17 KRT20
47 ameloblastic carcinoma 10.4 CDKN2A TP63
48 serous cystadenocarcinoma 10.4 MMP14 MMP2 TP53
49 nodular malignant melanoma 10.4 CDKN2A MMP14 MMP2
50 basal cell carcinoma, infundibulocystic 10.4 KRT17 KRT20

Graphical network of the top 20 diseases related to Actinic Keratosis:



Diseases related to Actinic Keratosis

Symptoms & Phenotypes for Actinic Keratosis

GenomeRNAi Phenotypes related to Actinic Keratosis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 CDKN2A CFLAR MCM2 PCNA TP53
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 CDKN2A CFLAR MCM2 PCNA TP53 TP63

MGI Mouse Phenotypes related to Actinic Keratosis:

43 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.29 MC1R CFLAR KRT17 CDKN2A LUM PCNA
2 cellular MP:0005384 10.27 CFLAR MC1R KRT17 CDKN2A LUM MMP14
3 behavior/neurological MP:0005386 10.24 CDKN2A LUM MC1R MMP14 MCM2 TP63
4 immune system MP:0005387 10.22 CFLAR MC1R CDKN2A LUM PCNA MMP14
5 hematopoietic system MP:0005397 10.19 CFLAR MC1R CDKN2A LUM PCNA MMP14
6 cardiovascular system MP:0005385 10.18 LUM CDKN2A CFLAR MMP14 MMP2 TP63
7 mortality/aging MP:0010768 10.17 CFLAR KRT17 CDKN2A LUM PCNA MMP14
8 digestive/alimentary MP:0005381 10.15 KRT17 CDKN2A LUM MMP14 PTGS2 MCM2
9 endocrine/exocrine gland MP:0005379 10.13 CFLAR CDKN2A PCNA MMP14 MCM2 TP53
10 integument MP:0010771 10.11 MC1R KRT17 CDKN2A LUM MMP14 PTGS2
11 embryo MP:0005380 10.08 CDKN2A CFLAR MMP14 MCM2 TP63 TP53
12 muscle MP:0005369 10.06 CFLAR MCM2 CDKN2A LUM MMP14 PTGS2
13 craniofacial MP:0005382 10.03 MC1R KRT17 MMP14 MMP2 TP63 TP53
14 no phenotypic analysis MP:0003012 9.97 MC1R KRT17 CDKN2A PCNA MMP14 PTGS2
15 neoplasm MP:0002006 9.91 MC1R CDKN2A PTGS2 MCM2 MMP2 TP53
16 normal MP:0002873 9.8 MMP14 MMP2 MCM2 TP63 TP53 PTGS2
17 pigmentation MP:0001186 9.55 MC1R KRT17 CDKN2A MCM2 TP53
18 respiratory system MP:0005388 9.5 CDKN2A MMP14 MCM2 MMP2 TP53 PTGS2
19 vision/eye MP:0005391 9.17 LUM CDKN2A MMP14 MMP2 TP53 PTGS2

Drugs & Therapeutics for Actinic Keratosis

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Picato gel 17 INGENOL MEBUTATE LEO Pharma January 2012

Drugs for Actinic Keratosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 189)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 106-60-5 137
2
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99011-02-6 57469
3
Fluorouracil Approved Phase 4,Phase 3,Early Phase 1 51-21-8 3385
4
Ethanol Approved Phase 4,Phase 2 64-17-5 702
5
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
6
Tacrolimus Approved, Investigational Phase 4,Phase 1,Phase 2 104987-11-3 445643 439492
7
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 1 15307-86-5 3033
8
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 69-72-7 338
9
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
10
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
11
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
12
Petrolatum Approved, Investigational Phase 4,Phase 2,Early Phase 1 8009-03-8
13
Alginic acid Approved, Experimental, Investigational Phase 4 9005-32-7
14
Everolimus Approved Phase 4,Phase 1,Phase 2 159351-69-6 6442177
15
Sirolimus Approved, Investigational Phase 4,Phase 1,Phase 2 53123-88-9 46835353 6436030 5284616
16
Menthol Approved Phase 4 2216-51-5 16666
17
Mycophenolic acid Approved Phase 4 24280-93-1 446541
18
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
19
Azathioprine Approved Phase 4 446-86-6 2265
20
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 68-26-8, 11103-57-4 445354
21
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 1406-16-2
22
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 10883523 5280795 6221
23
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1 50-14-6 5280793
24 interferons Phase 4,Phase 3,Phase 2,Phase 1
25 Methyl 5-aminolevulinate Phase 4,Phase 3,Phase 2,Phase 1
26 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
27 Sunscreening Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
30 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Antimetabolites Phase 4,Phase 3,Phase 2,Early Phase 1
33 Antimetabolites, Antineoplastic Phase 4,Phase 3,Early Phase 1
34 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1
35 Protective Agents Phase 4,Phase 3,Phase 2
36 Radiation-Protective Agents Phase 4,Phase 2
37 Clofibric Acid Phase 4 882-09-7
38 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
39 Retinol palmitate Phase 4,Phase 3,Phase 2
40 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
43 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
44 Viscosupplements Phase 4
45 Vitamins Phase 4,Phase 2,Phase 1,Early Phase 1
46 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
47 Emollients Phase 4,Phase 2,Early Phase 1
48 Anticholesteremic Agents Phase 4,Phase 2
49 Ergocalciferols Phase 4,Phase 1
50 Hypolipidemic Agents Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 339)

# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel Unknown status NCT02647151 Phase 4 METHYLAMINOLEVULINATE HYDROCHLORIDE;AMINOLEVULINIC ACID HYDROCHLORIDE
2 Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
3 Long Term Efficacy and Safety of Eryfotona AK-NMSC® in Patients With Actinic Keratosis Unknown status NCT01656226 Phase 4
4 Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4 Imiquimod cream 3.75%;Placebo cream
5 Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) Completed NCT02464709 Phase 4 Aminolevulinic Acid;Methyl 5-aminolevulinate
6 Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015% Completed NCT02446223 Phase 4 Inggenol Mebutate 0.015%
7 Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses Completed NCT03327831 Phase 4 Aminolevulinic Acid
8 Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis Completed NCT02716714 Phase 4 ingenol mebutate gel 0.015%;ingenol mebutate gel 0.05%
9 Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
10 Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis Completed NCT00116649 Phase 4 imiquimod cream
11 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT) Completed NCT01000636 Phase 4
12 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2) Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
13 Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses Completed NCT02251652 Phase 4 Ingenol Mebutate
14 Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times Completed NCT02622594 Phase 4 Aminolevulinic Acid (ALA)
15 Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses Completed NCT00777127 Phase 4 Imiquimod;Diclofenac
16 Effects of Topical Diclofenac on Tumor Metabolism Completed NCT01935531 Phase 4 3% diclofenac in 2.5% hyaluronic acid gel
17 Study of Imiquimod 5% Cream in Addition to Cryotherapy in the Management of Actinic Keratoses Completed NCT00110682 Phase 4 Imiquimod used as an adjunct to cryotherapy
18 Clinical Trial to Evaluate Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy Completed NCT00695578 Phase 4 Biafine
19 An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses Completed NCT00377273 Phase 4 fluorouracil cream 0.5%
20 Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head Completed NCT00204542 Phase 4 Diclofenac;Diclofenac
21 Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Arms and Hands Completed NCT00115154 Phase 4 Aldara (imiquimod) cream, 5%
22 Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp Completed NCT02406014 Phase 4 Ingenol Mebutate Gel, 0.015%;Diclofenac sodium gel 3%
23 Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population Completed NCT00696488 Phase 4 Fluorouracil 0.5%
24 Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
25 Zurich Multiple Endpoint Vitamin D Trial in Knee OA Patients Completed NCT00599807 Phase 4
26 The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) Completed NCT01527318 Phase 4 Fibrate treatment
27 Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents Recruiting NCT03279328 Phase 4 Topical Steroid Ointment;Skin Barrier Moisturier
28 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients Recruiting NCT02866695 Phase 4 ingenol mebutate gel 0.015%
29 Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy Active, not recruiting NCT02990221 Phase 4 Ingenol mebutate
30 IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis Active, not recruiting NCT02281682 Phase 4 Imiquimod;5-fluorouracil;Ingenol mebutate
31 Daylight-PDT With MAL for AK and Photodamaged Skin Active, not recruiting NCT02736760 Phase 4 Daylight photodynamic therapy using Methylaminolevulinate (MAL)
32 Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5% Active, not recruiting NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
33 Menthol for PDT Pain Not yet recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
34 Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients Terminated NCT01538901 Phase 4 imiquimod 5% cream
35 Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Terminated NCT01203878 Phase 4 Photodynamic therapy;Imiquimod
36 Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study Terminated NCT00944216 Phase 4 Salkera Emollient Foam
37 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
38 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
39 Actinic Keratoses Treatment With Metvix® in Combination With Light Unknown status NCT02373371 Phase 3 Metvix®
40 T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum Unknown status NCT00002811 Phase 3 liposomal T4N5 lotion
41 5fluorouracil for Advanced Photoaging Unknown status NCT01405144 Phase 3 5-fluoruracil
42 A Study of the Clinicopathologic Behaviour of the Different Types of Unsafe Chronic Otitis Media Unknown status NCT00270660 Phase 3
43 Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous Unknown status NCT01222000 Phase 3 apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side;apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
44 A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations Completed NCT00942604 Phase 3 PEP005 (ingenol mebutate) Gel;Vehicle gel
45 A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations Completed NCT00742391 Phase 3 PEP005 (ingenol mebutate) Gel;Vehicle gel
46 Comparison Between 5-aminolevulinic Acid Photodynamic Therapy Versus Cryotherapy for Actinic Keratosis Treatment Completed NCT01459393 Phase 3 5-ALA Photodynamic Therapy;Cryotherapy with liquid nitrogen
47 Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses Completed NCT02289768 Phase 3 5-fluorouracil/salicylic acid;Vehicle
48 Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis Completed NCT02616601 Phase 3 Carac Cream;Generic Fluorouracil Cream;Placebo
49 Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities Completed NCT02137785 Phase 3 Aminolevulinic Acid (ALA);Topical Solution Vehicle
50 Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest Completed NCT02361216 Phase 3 Ingenol Mebutate

Search NIH Clinical Center for Actinic Keratosis

Cochrane evidence based reviews: keratosis, actinic

Genetic Tests for Actinic Keratosis

Anatomical Context for Actinic Keratosis

MalaCards organs/tissues related to Actinic Keratosis:

38
Skin, Testes, Kidney, T Cells, Neutrophil, Liver, Bone

Publications for Actinic Keratosis

Articles related to Actinic Keratosis:

(show top 50) (show all 577)
# Title Authors Year
1
Actinic Keratosis and Non-Invasive Diagnostic Techniques: An Update. ( 29316678 )
2018
2
Cost-efficacy analysis of 3% diclofenac sodium, ingenol mebutate, and 3.75% imiquimod in the treatment of actinic keratosis. ( 29442526 )
2018
3
Daylight-Mediated Photodynamic Therapy With Methyl Aminolevulinate in Actinic Keratosis Treatment. ( 29351725 )
2018
4
Daylight photodynamic therapy: experience in the treatment of actinic keratosis in San Gallicano Institute of Rome and a review of literature. ( 29368865 )
2018
5
Topical formulations of delta-aminolevulinic acid for the treatment of actinic keratosis: Characterization and efficacy evaluation. ( 29407554 )
2018
6
Tracking actinic keratosis of face and scalp treated with 0.015% ingenol mebutate to identify clinical and dermoscopic predictors of treatment response. ( 29356164 )
2018
7
A multi-centre, open, investigator initiated phase IV clinical trial to evaluate the efficacy and safety of ingenol mebutate gel, 0.015% on the face and scalp, and 0.05% on the trunk and extremities, in Korean patients with actinic keratosis (PERFECT). ( 29355904 )
2018
8
Self-expressed patient preferences for the treatment of actinic keratosis: results from a non-interventional study based on a real-life setting in Spain. ( 29402758 )
2018
9
Detection of human papillomavirus in actinic keratosis. ( 29383738 )
2018
10
Evaluation of T lymphocyte subpopulations in Actinic Keratosis, In Situ and Invasive Squamous Cell Carcinoma of the Skin. ( 29419888 )
2018
11
Daylight Photodynamic Therapy Versus 5-Fluorouracil for the Treatment of Actinic Keratosis: A Case Series. ( 29322431 )
2018
12
Treating actinic keratosis: assessment of effectiveness, discomfort, costs and follow-up. ( 29441544 )
2018
13
Astragalin attenuates UVB radiation-induced Actinic Keratosis formation. ( 29298652 )
2017
14
Actinic keratosis modelling in mice: A translational study. ( 28662116 )
2017
15
Patient satisfaction and reported outcomes on the management of actinic keratosis. ( 28553130 )
2017
16
Prevalence and risk factors of actinic keratosis in patients attending Italian dermatology clinics. ( 29311040 )
2017
17
Rosettes in actinic keratosis and squamous cell carcinoma: distribution, association to other dermoscopic signs and description of the rosette pattern. ( 28707711 )
2017
18
Photodynamic Therapy Effective for the Treatment of Actinic Keratosis and Basal Cell Carcinoma in Bullous Pemphigoid Patients. ( 28373119 )
2017
19
In-clinic application of ingenol mebutate 0.015% gel for actinic keratosis in large areas of the face is feasible and attracts a high rate of patient satisfaction: Results of a questionnaire. ( 28776637 )
2017
20
Safety and Efficacy of Escalating Doses of Ingenol Mebutate for Field Treatment of Actinic Keratosis on the Full Face, Full Balding Scalp, or Chest. ( 28628679 )
2017
21
In vivo microvascular imaging of cutaneous actinic keratosis, Bowen's disease and squamous cell carcinoma using dynamic optical coherence tomography. ( 28502083 )
2017
22
Assessment of Efficacy and Irritation of Ingenol Mebutate Gel 0.015% Used With or Without Dimethicone Lotion for Treatment of Actinic Keratosis on the Face. ( 28628678 )
2017
23
Treatment of Multiple Actinic Keratosis and Field of Cancerization with Topical Piroxicam 0.8% and Sunscreen 50+ in Organ Transplant Recipients: A Series of 10 Cases. ( 29282394 )
2017
24
Epithelial-to-mesenchymal transition contributes to invasion in squamous cell carcinomas originated from actinic keratosis through the differentiated pathway, whereas proliferation plays a more significant role in the classical pathway. ( 28796927 )
2017
25
Dermoscopy of Pigmented Actinic Keratosis of the Face: A Study of 232 Cases. ( 28705516 )
2017
26
Acantholytic squamous cell carcinoma is usually associated with hair follicles, not acantholytic actinic keratosis, and is not "high risk": Diagnosis, management, and clinical outcomes in a series of 115 cases. ( 27889291 )
2017
27
A seamless Phase I/II dose-finding trial assessing ingenol disoxate (LEO 43204) for field treatment of actinic keratosis on the scalp. ( 28078678 )
2017
28
Actinic keratosis. Or maybe not? ( 28556349 )
2017
29
New and current preventive treatment options in actinic keratosis. ( 28805940 )
2017
30
Three-day Field Treatment with Ingenol Disoxate (LEO 43204) for Actinic Keratosis: A Phase II Trial. ( 29399263 )
2017
31
A review of BF-200 ALA for the photodynamic treatment of mild-to-moderate actinic keratosis. ( 28805092 )
2017
32
A Novel Actinic Keratosis Field Assessment Scale for Grading Actinic Keratosis Disease Severity. ( 28536731 )
2017
33
Chemical Proteomics Identifies SLC25A20 as a Functional Target of the Ingenol Class of Actinic Keratosis Drugs. ( 29296668 )
2017
34
Phasor-FLIM as a Screening Tool for the Differential Diagnosis of Actinic Keratosis, Bowen's Disease, and Basal Cell Carcinoma. ( 28661125 )
2017
35
CD40 Ligand Is Increased in Mast Cells in Psoriasis and Actinic Keratosis but Less So in Epithelial Skin Carcinomas. ( 28267402 )
2017
36
Prevalence of actinic keratosis in a French cohort of elderly people: the PROOF study. ( 28906092 )
2017
37
Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update. ( 27785771 )
2017
38
Patient-reported outcomes in topical field treatment of actinic keratosis in Swedish and Danish patients. ( 28658998 )
2017
39
Photodynamic therapy is more effective than imiquimod for actinic keratosis in organ transplant recipients - a randomized intra-individual controlled trial. ( 28796885 )
2017
40
Predictors of actinic keratosis count in patients with multiple keratinocyte carcinomas: A cross-sectional study. ( 28088997 )
2017
41
Field treatment of actinic keratosis on the scalp. ( 28581227 )
2017
42
Photodynamic therapy for actinic keratosis: Is the European consensus protocol for daylight PDT superior to conventional protocol for Aktilite CL 128 PDT? ( 28756154 )
2017
43
Dermatoscopic Patterns of Nonfacial Actinic Keratosis: Characterization of Pigmented and Nonpigmented Lesions. ( 28538027 )
2017
44
Human papilloma virus expression in immunocompetent patients with actinic keratosis: A case series. ( 28917462 )
2017
45
Three-Day Field Treatment with Ingenol Disoxate (LEO 43204) for Actinic Keratosis: Cosmetic Outcomes and Patient Satisfaction from a Phase II Trial. ( 29399258 )
2017
46
Noninvasive Long-term Monitoring of Actinic Keratosis and Field Cancerization Following Treatment with Ingenol Mebutate Gel 0.015. ( 29344318 )
2017
47
Actinic Keratosis. ( 27046367 )
2016
48
Randomized controlled trial comparing 35% trichloroacetic acid peel and 5-aminolevulinic acid photodynamic therapy for the treatment of multiple actinic keratosis. ( 28012181 )
2016
49
Use of Lesion Response Rate in Actinic Keratosis Trials. ( 27645828 )
2016
50
Case of Japanese Hermansky-Pudlak syndrome patient with deeply invasive squamous cell carcinoma and multiple lesions of actinic keratosis on the face and neck. ( 27178242 )
2016

Variations for Actinic Keratosis

Cosmic variations for Actinic Keratosis:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM45765 TP53 skin,leg,carcinoma,squamous cell carcinoma c.987C>A p.T329T 3
2 COSM10863 TP53 skin,leg,carcinoma,squamous cell carcinoma c.833C>T p.P278L 3
3 COSM45114 TP53 skin,leg,carcinoma,squamous cell carcinoma c.702C>A p.Y234* 3
4 COSM573 NRAS skin,scalp,carcinoma,squamous cell carcinoma c.38G>A p.G13D 3
5 COSM521 KRAS skin,scalp,carcinoma,squamous cell carcinoma c.35G>A p.G12D 3
6 COSM554 KRAS skin,scalp,carcinoma,squamous cell carcinoma c.183A>C p.Q61H 3
7 COSM499 HRAS skin,trunk,carcinoma,squamous cell carcinoma c.182A>G p.Q61R 3
8 COSM498 HRAS skin,trunk,carcinoma,squamous cell carcinoma c.182A>T p.Q61L 3
9 COSM12475 CDKN2A skin,leg,carcinoma,squamous cell carcinoma c.238C>T p.R80* 3

Expression for Actinic Keratosis

Search GEO for disease gene expression data for Actinic Keratosis.

Pathways for Actinic Keratosis

GO Terms for Actinic Keratosis

Cellular components related to Actinic Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 replication fork GO:0005657 8.96 PCNA TP53
2 extracellular matrix GO:0031012 8.92 LUM MMP14 MMP2 TNC

Biological processes related to Actinic Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.73 CDKN2A CFLAR KRT20 MCM2 TP53 TP63
2 cellular response to hypoxia GO:0071456 9.58 CFLAR PTGS2 TP53
3 intermediate filament organization GO:0045109 9.48 KRT17 KRT20
4 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.46 CFLAR TMC8
5 response to oxidative stress GO:0006979 9.46 MMP14 PCNA PTGS2 TP53
6 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.43 TP53 TP63
7 replicative senescence GO:0090399 9.37 CDKN2A TP53
8 mitotic G1 DNA damage checkpoint GO:0031571 9.32 TP53 TP63
9 response to organic cyclic compound GO:0014070 9.26 LUM MMP14 PTGS2 TP53
10 cellular response to UV GO:0034644 8.92 PCNA PTGS2 TP53 TP63

Molecular functions related to Actinic Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.56 MCM2 PCNA PTGS2 TP53
2 protein binding GO:0005515 9.5 CDKN2A CFLAR KRT17 KRT20 LUM MC1R
3 MDM2/MDM4 family protein binding GO:0097371 9.16 TP53 TP63
4 damaged DNA binding GO:0003684 9.13 PCNA TP53 TP63

Sources for Actinic Keratosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....